PFE25.33-1.63%
PFE · US
1y range: 25.33 → 28.55 · as of 2026-05-15
Next earnings
2026-08-03
in 76d
Recent material news
- BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM2026-05-15T16:10
- 5 Must-Read Analyst Questions From Pfizer’s Q1 Earnings Call2026-05-15T08:52
- Pfizer Gets Expanded European OK for Hympavzi Hemophilia Drug2026-05-13T07:11
- Pfizer Receives European Commission Marketing Authorization To Expand The Approved Indication For HYMPVAZI To Include Patients 12 Years Of Age And Older Weighing At Least 35KG With Hemophilia A With FVIII Inhibitors Or Hemophilia B With FIX Inhibitors2026-05-13T06:48
- Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)2026-05-12T07:02
- How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story2026-05-07T04:33
- Pfizer Inc. (PFE) Q1 2026 Earnings Call Transcript2026-05-05T14:01
- Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance2026-05-05T10:45
Want this depth on every stock you watch?
ThickerPeek writes a daily AI digest on 165+ stocks, weekly theses, earnings briefings, and alerts — for €19/mo. Free tier available.
Not investment advice. ThickerPeek is a research tool. AI-written content is informational, not a buy/sell recommendation. Investment decisions are your own responsibility.